Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability

BACKGROUND AND OBJECTIVES: Children with multiple sclerosis (MS) are increasingly treated with high-efficacy monoclonal antibody therapies; however, treatment approaches vary widely, largely because of regulatory restrictions that often delay access until adulthood. We hypothesized that initiating these therapies during childhood confers greater benefits than their initiation in adulthood. This study, therefore, evaluated long-term disability in patients with pediatric-onset MS treated with monoclonal antibodies before age 18 compared with those who initiated these therapies in adulthood. METHODS: In this retrospective cohort study, patients younger than 18 years at the onset of MS symptoms were identified across 3 MS registries: MSBase, Observatoire Français de la Sclérose en Plaques, and the Italian MS Register. We categorized patients who commenced natalizumab, ocrelizumab, or rituximab between ages 12 and 17 into the pediatric high-efficacy therapy (HET) initiation group and those who began treatment between ages 20 and 22 into the adult HET initiation group. A landmark study design was used, with age 18 designated as the baseline and the outcome period spanning ages 23-27 years. The primary outcome was the change in Expanded Disability Status Scale (EDSS) scores, evaluated using a Bayesian weighted generalized linear mixed model. RESULTS: We included 277 patients (72% female), with a mean (SD) age at onset of MS symptoms of 14.97 (2.23) years. Of these, 108 initiated HET during childhood and 169 during adulthood. The postbaseline increase in EDSS scores was 0.53 steps lower in the pediatric HET initiation group compared with the adult group (β -0.53 [95% credible interval -0.87 to -0.19]). This benefit of pediatric HET initiation was most pronounced within the EDSS range of 4.5-6.0, with up to a 97% reduction in the odds of further disability worsening (odds ratio of EDSS score 5.0 over 4.5: 0.03 [95% credible interval 0.003-0.22]). DISCUSSION: Commencing high-efficacy monoclonal antibody therapy in childhood is associated with more favorable long-term disability outcomes than delayed initiation in adulthood. Early use of highly effective therapy is crucial for preserving neurologic function in children with MS. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, in children aged 12-17 years with MS, initiating therapy with monoclonal antibodies before age 18 (vs 20-22) is associated with less disability accrual between the ages of 23 and 27.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2026-05-29
DOI
https://doi.org/10.1212/wnl.0000000000218056
Citations
1
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
14.98
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability

Pierre Labauge, Sifat Sharmin, María Trojano, Pietro Iaffaldano et al.
1 citations
Neurology
Multiple Sclerosis Research Studies
14.98
article

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability

Pierre Labauge, Sifat Sharmin, María Trojano, Pietro Iaffaldano, Izanne Roos, Carlo Pozzilli, Paola Perini, David Axel Laplaud, Tomas Kalincik, for the MSBase, OFSEP, and Italian Multiple Sclerosis Registry Investigators, Vincenzo Brescia Morra, Marta Simone, Maria Pia Amato, Raed Alroughani, Laurent Magy, Emilio Portaccio, Francesco Patti, Massimo Filippi, Christine Lebrun-Frenay, Anneke Van Der Walt, Davide Maimone, Eric Manchon, Sara Eichau, Helmut Butzkueven, Sandra Vukusic, Kumaran Deiva
article en
1 citations

Abstract

BACKGROUND AND OBJECTIVES: Children with multiple sclerosis (MS) are increasingly treated with high-efficacy monoclonal antibody therapies; however, treatment approaches vary widely, largely because of regulatory restrictions that often delay access until adulthood. We hypothesized that initiating these therapies during childhood confers greater benefits than their initiation in adulthood. This study, therefore, evaluated long-term disability in patients with pediatric-onset MS treated with monoclonal antibodies before age 18 compared with those who initiated these therapies in adulthood. METHODS: In this retrospective cohort study, patients younger than 18 years at the onset of MS symptoms were identified across 3 MS registries: MSBase, Observatoire Français de la Sclérose en Plaques, and the Italian MS Register. We categorized patients who commenced natalizumab, ocrelizumab, or rituximab between ages 12 and 17 into the pediatric high-efficacy therapy (HET) initiation group and those who began treatment between ages 20 and 22 into the adult HET initiation group. A landmark study design was used, with age 18 designated as the baseline and the outcome period spanning ages 23-27 years. The primary outcome was the change in Expanded Disability Status Scale (EDSS) scores, evaluated using a Bayesian weighted generalized linear mixed model. RESULTS: We included 277 patients (72% female), with a mean (SD) age at onset of MS symptoms of 14.97 (2.23) years. Of these, 108 initiated HET during childhood and 169 during adulthood. The postbaseline increase in EDSS scores was 0.53 steps lower in the pediatric HET initiation group compared with the adult group (β -0.53 [95% credible interval -0.87 to -0.19]). This benefit of pediatric HET initiation was most pronounced within the EDSS range of 4.5-6.0, with up to a 97% reduction in the odds of further disability worsening (odds ratio of EDSS score 5.0 over 4.5: 0.03 [95% credible interval 0.003-0.22]). DISCUSSION: Commencing high-efficacy monoclonal antibody therapy in childhood is associated with more favorable long-term disability outcomes than delayed initiation in adulthood. Early use of highly effective therapy is crucial for preserving neurologic function in children with MS. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, in children aged 12-17 years with MS, initiating therapy with monoclonal antibodies before age 18 (vs 20-22) is associated with less disability accrual between the ages of 23 and 27.

NeurologyVol. 106(12)
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), The Royal Melbourne Hospital (AU), University of Padua (IT), Vita-Salute San Raffaele University (IT), Inserm (FR), The University of Melbourne (AU), Université de Montpellier (FR), Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR), Multiple Sclerosis Foundation (US), The Alfred Hospital (AU), Victorian Curriculum and Assessment Authority (AU), Amiri Hospital (KW), Centre Hospitalier Universitaire de Nice (FR), University of Catania (IT), Hospital Universitario Virgen Macarena (ES), Centre Hospitalier Universitaire de Montpellier (FR), Centre de Recherche en Neurosciences de Lyon (FR), Centre de Référence des Maladies Autoinflammatoires et des Amyloses (FR), Observatoire Français de la Sclérose en Plaques (FR), Don Carlo Gnocchi Foundation (IT), Centre Hospitalier de Gonesse (FR), Centre d'Investigation Clinique de Nantes (FR), CEA Paris-Saclay (FR), Infectious Disease Models and Innovative Therapies (FR), Policlinico Universitario di Catania (IT), IRCCS Ospedale San Raffaele (IT), Ospedale Cannizzaro (IT), Hôpital Dupuytren (FR), Bicêtre Hospital (FR), University of Florence (IT), University of Bari Aldo Moro (IT), Monash University (AU), University of Naples Federico II (IT), Sapienza University of Rome (IT), Nantes Université (FR)
Openalex Percentile: Top 1%
Multiple Sclerosis Research Studies
14.98
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.